VC trio de­buts seed fund; Take­da cuts ear­ly gene ther­a­py work; Bio­gen’s new face of BD; Biotech in­vestors get hands on; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

By now, most, if not all, of you will have heard about the ex­cit­ing news that End­points has joined the Fi­nan­cial Times fam­i­ly. Thank you for all of your sup­port over the years — and now, on­to greater things!

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER